BELLICUM PHARMACEUTICALS INC's ticker is BLCM and the CUSIP is 079481107. A total of 81 filers reported holding BELLICUM PHARMACEUTICALS INC in Q4 2015. The put-call ratio across all filers is 0.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $208,000 | +5.1% | 61,666 | -9.0% | 0.00% | – |
| Q4 2018 | $198,000 | -47.3% | 67,770 | +11.2% | 0.00% | -100.0% |
| Q3 2018 | $376,000 | -16.4% | 60,961 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $450,000 | +63.6% | 60,961 | +45.2% | 0.00% | 0.0% |
| Q1 2018 | $275,000 | -24.2% | 41,996 | -2.7% | 0.00% | 0.0% |
| Q4 2017 | $363,000 | -29.7% | 43,146 | -3.4% | 0.00% | 0.0% |
| Q3 2017 | $516,000 | -8.2% | 44,646 | -7.3% | 0.00% | 0.0% |
| Q2 2017 | $562,000 | +10.4% | 48,146 | +16.7% | 0.00% | 0.0% |
| Q1 2017 | $509,000 | -13.6% | 41,246 | -4.6% | 0.00% | 0.0% |
| Q4 2016 | $589,000 | -33.2% | 43,246 | -2.5% | 0.00% | -50.0% |
| Q3 2016 | $882,000 | +54.7% | 44,346 | +0.9% | 0.00% | +100.0% |
| Q2 2016 | $570,000 | +243.4% | 43,946 | +147.3% | 0.00% | – |
| Q1 2016 | $166,000 | -46.6% | 17,768 | +15.7% | 0.00% | -100.0% |
| Q4 2015 | $311,000 | +42.7% | 15,362 | +2.4% | 0.00% | 0.0% |
| Q3 2015 | $218,000 | -32.1% | 15,008 | -0.7% | 0.00% | 0.0% |
| Q2 2015 | $321,000 | -10.1% | 15,108 | -1.9% | 0.00% | 0.0% |
| Q1 2015 | $357,000 | – | 15,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 918,000 | $11,328,000 | 4.35% |
| EMORY UNIVERSITY | 164,607 | $2,031,000 | 1.92% |
| Monashee Investment Management LLC | 160,000 | $1,974,000 | 0.79% |
| UNIVERSITY OF NOTRE DAME DU LAC | 210,260 | $2,595,000 | 0.65% |
| CORRADO ADVISORS, LLC | 83,622 | $1,032,000 | 0.59% |
| Foresite Capital Management II, LLC | 105,000 | $1,296,000 | 0.56% |
| Baker Brothers Advisors | 5,032,313 | $62,099,000 | 0.51% |
| SPHERA FUNDS MANAGEMENT LTD. | 200,000 | $2,468,000 | 0.48% |
| Clearline Capital LP | 55,200 | $681,000 | 0.32% |
| LMR Partners LLP | 270,594 | $3,339,000 | 0.32% |